Literature DB >> 20386249

Cholesterol and triglyceride management: "if I take my medication, can I eat what I want?".

Lynne T Braun1.   

Abstract

The medications we use for cholesterol and triglyceride lowering are powerful and have substantial outcome data. However, even with aggressive statin therapy, there is residual risk for recurrent cardiovascular events. Strict dietary modification has been shown to reduce low-density lipoprotein (LDL) cholesterol by 20% to 30%. Low-fat and Mediterranean-type diets have also been associated with atherosclerosis regression and fewer coronary heart disease events. On the other hand, a high-fat diet can produce postprandial lipemia and an increase in cardiovascular disease risk. Patients with atherogenic dyslipidemia (low high-density lipoprotein cholesterol, increased triglycerides and non-high-density lipoprotein cholesterol, small dense low-density lipoprotein particles) and visceral adiposity are particularly prone to postprandial lipemia. These individuals typically have insulin resistance, which is associated with endothelial dysfunction and an increased risk for thrombosis. Lifestyle intervention is the key to reducing postprandial lipemia, specifically weight reduction and increased physical activity. Although medications can improve postprandial lipemia, poor dietary choices can overwhelm the effects of medication and negatively impact the health of arteries, thus promoting atherosclerosis. Therefore, patients who are treated with medications for dyslipidemia must be counseled on consuming a heart-healthy diet.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20386249     DOI: 10.1097/JCN.0b013e3181cec6d1

Source DB:  PubMed          Journal:  J Cardiovasc Nurs        ISSN: 0889-4655            Impact factor:   2.083


  5 in total

1.  A specific nursing educational program in patients with Cushing's syndrome.

Authors:  M Antonia Martínez-Momblán; Carmen Gómez; Alicia Santos; Nuria Porta; Julia Esteve; Inmaculada Úbeda; Irene Halperin; Beatriz Campillo; Montserrat Guillaumet; Susan M Webb; Eugenia Resmini
Journal:  Endocrine       Date:  2015-09-23       Impact factor: 3.633

2.  DDDAS Design of Drug Interventions for the Treatment of Dyslipidemia in ApoE-/- Mice.

Authors:  Brittney Metts; Sean Thatcher; Eboni Lewis; Mike Karounos; Lisa Cassis; Rebecca Smith; Robert A Lodder
Journal:  J Dev Drugs       Date:  2013-10

Review 3.  The autoimmune concept of atherosclerosis.

Authors:  Cecilia Grundtman; Georg Wick
Journal:  Curr Opin Lipidol       Date:  2011-10       Impact factor: 4.776

4.  Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice.

Authors:  Ganesan Murali; Ginger L Milne; Corey D Webb; Ann B Stewart; Ryan P McMillan; Brandon C Lyle; Matthew W Hulver; Viswanathan Saraswathi
Journal:  J Lipid Res       Date:  2012-07-29       Impact factor: 5.922

5.  Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases.

Authors:  Boudewijn Klop; Spencer D Proctor; John C Mamo; Kathleen M Botham; Manuel Castro Cabezas
Journal:  Int J Vasc Med       Date:  2011-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.